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Edited by Lukas HuberAbstract We demonstrate that human umbilical vein endothe-
lial cells (HUVEC) grown in co-culture (CC) with U87
glioblastoma cells transfected with green ﬂuorescent protein
(GFP-U87) exhibit resistance to radiation-mediated apoptosis.
cDNA macroarray analysis reveals increases in the accumulation
of RNAs for HUVEC genes encoding cell adhesion molecules,
growth factor-related proteins, and cell cycle regulatory/DNA
repair proteins. An increase in protein expression of integrin av,
integrin b1, MAPK(p42), Rad51, DNA-PKCS, and ataxia
telangiectasia gene (ATM) was detected in HUVEC grown in
CC with GFP-U87 cells compared with HUVEC grown in
mono-culture. Treatment with anti-VEGF antibody decreases
the expression of integrin av, integrin b1, DNA-PKCS and ATM
with a corresponding increase in ionizing radiation (IR)-induced
apoptosis. These data support the concept that endothelial cells
growing in the tumor microenvironment may develop resistance
to cytotoxic therapies due to the up-regulation by tumor cells of
endothelial cells genes associated with survival.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Numerous studies have shown that the tumor vasculature is a
potential target for therapy [1]. Although the precise role of
angiogenesis inhibitors as a sole treatment for cancer is con-
troversial, experimental evidence suggests that anti-angiogenic
compounds enhance the anti-tumor eﬀects of ionizing radiation
(IR) [2–4].Anti-tumor eﬀects have also been reportedwhen IR is
combined with neutralizing antibodies to vascular endothelial
growth factor (VEGF) [5,6], VEGF receptor 2 antibodies [7,8],
blocking peptides [9,10], tyrosine kinase inhibitors [11], and
dominant-negative mutant receptor constructs [12]. We inves-
tigated whether tumor cells inﬂuence the expression of endo-
thelial cell genes by growing human umbilical vein endothelial
cells (HUVEC) in co-culture (CC)withU87 glioblastoma tumor
cells transfected with green ﬂuorescent protein (GFP-U87). We* Corresponding author. Fax: +1-773-702-1968.
E-mail address: hmauceri@rover.uchicago.edu (H.J. Mauceri).
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doi:10.1016/j.febslet.2004.03.099report that HUVEC exhibit increased resistance to IR-mediated
apoptosis following CC with GFP-U87 cells. Using cDNA
macroarray analysis, we identiﬁed 8 HUVEC genes whose
RNAs are accumulated >10-fold following CC with GFP-U87
cells. These genes encode integrin proteins and proteins involved
in critical pathways of DNA repair, recombination and check-
point control. Furthermore, our results indicate that VEGF
secretion by GFP-U87 cells alters the expression of these en-
dothelial cell genes.We propose that tumor cell up-regulation of
endothelial cell genes associated with survival following IR
exposure may mediate tumor-associated endothelial cell radio-
resistance and, therefore, contribute to the overall resistance
of tumors to radiotherapy.2. Materials and methods
2.1. Cell culture and transfection
Human umbilical vein endothelial cells were purchased from Clo-
netics (Walkerville, MD) and maintained in EGM-2 medium (Clo-
netics). EGM-2 medium contains EBM-2 medium (serum-free, growth
factor-free), supplemented with 2% fetal bovine serum (FBS), human
ﬁbroblast growth factor-B (hFGF-B), human epidermal growth factor
(hEGF), human vascular endothelial cell growth factor (hVEGF), long
R insulin-like growth factor-1 (R3-IGF-1), ascorbic acid, hydrocorti-
sone and heparin. All HUVEC used in these experiments were passage
4 or less. GFP-U87 cells are stable transformants of U87MG glio-
blastoma cells (a gift from the UCSF Brain Tumor Tissue Bank, San
Francisco, CA) transfected with GFP to aid in the discrimination of
these cells as previously described [13]. Transfection was performed by
standard methods using LIPOFECTIN reagent (Invitrogen, Carls-
bad, CA) and the pEGFP-C1 vector system (Clontech, Palo Alto, CA).
GFP-U87 tumor cells were maintained in low glucose Dulbecco’s
Modiﬁed Eagle’s Medium (Gibco-Invitrogen, Grand Island, NY)
supplemented with 10% FBS (Serologicals Corp., Norcross, GA), 1%
non-essential amino acids (Gibco-Invitrogen), and 400 lg/ml G418
(Sigma, St. Louis, MO). Monolayer cells were disaggregated into single
cells and counted using a ﬂuorescent microscope to discriminate GFP-
ﬂuorescent U87 tumor cells from the non-ﬂuorescent HUVEC.
2.2. CC of HUVEC with GFP-U87 cells
CC was performed in serum-free, growth factor-free EBM-2 me-
dium. Before CC was initiated, both cell types were washed three times
with EBM-2 medium. Two CC conditions were employed in the cur-
rent studies: (1) ‘‘physically combined’’ CC in which GFP-U87 cells
were cultured in the same ﬂasks with HUVEC cells and (2) ‘‘physically
separated’’ CC employing TransWell chambers (0.4 lm pores,
Corning Costar, Cambridge, MA) with GFP-U87 cells loaded in the
bottom wells and HUVEC loaded in the inserts. Our previous pub-
lished data demonstrate that an ‘‘activated’’ HUVEC phenotype is
achieved in both CC conditions [13].ation of European Biochemical Societies.
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HUVEC cultures were grown in EGM-2 medium overnight and the
next day washed three times with EBM-2 medium. GFP-U87 cells were
disaggregated into a single cell suspension using trypsin:EDTA, wa-
shed three times with EBM-2 medium and added to HUVEC cultures
growing in EBM-2 medium to establish ‘‘physically separated’’ CC
employing TransWell chambers. 3 h later, cultures were treated with
a single IR dose of 300 cGy using a Pantak PMC 1000 X-ray generator
operating at 250 kVp, 15 mA with a 0.5 mm copper ﬁlter. Following
irradiation, cells were incubated for 24 h.
2.4. HUVEC puriﬁcation
HUVEC grown in mono-culture (MC) or CC with GFP-U87 cells
were disaggregated into single cell suspensions, washed two times with
PBS containing 0.1% BSA, and isolated using superparamagnetic
polystyrene beads coated with anti-CD31 monoclonal antibody
(Dynabeads CD31, Dynal Biotech, Oslo, Norway) according to the
manufacturer’s protocol. Eﬃcacy of HUVEC separation from GFP-
U87 cells in CC was determined by counting the number of ﬂuorescent
GFP-U87 cells and non-ﬂuorescent HUVEC cells using a hemocy-
tometer. In independent experiments eﬃcacy ranged from 97% to 99%.
2.5. Apoptosis detection
Apoptosis was evaluated using ‘‘physically separated’’ CCs. HU-
VEC growing in EGM-2 medium were plated in TransWell inserts on
day 1 and 24 h later HUVEC or GFP-U87 cells in EBM-2 medium
were plated in TransWell chambers at the ratio of 1:10 insert:cham-
ber. Three hours later, cultures were treated with a single IR dose of
300 cGy as described above. HUVEC apoptosis was scored 24 h after
IR exposure (27 h after establishment of CC). Floating and attached
HUVEC were harvested by centrifugation at 1500 rpm for 5 min.
Membranes were cut from the inserts and mounted on glass slides.
After applying Vectashield containing DAPI (Vector Labs, Burlin-
game, CA), coverslips were placed on membranes and slides were in-
cubated for 30 min in the dark. HUVEC were photographed at 10
magniﬁcation and apoptotic bodies were evaluated in 10 ﬁelds from
each of duplicate membranes.
2.6. cDNA macroarray
HUVEC were grown to 70–80% conﬂuence in EGM-2 medium.
GFP-U87 cells were added to HUVEC at a ratio of 1:20 to establish
‘‘physically combined’’ CCs. 48 h later, HUVEC were isolated from
GFP-U87 cells using anti-CD31 coated superparamagnetic polystyrene
beads as described above. RNA preparation, cDNA generation and
hybridization of the AtlasTM cDNA expression arrays were performed
according to the manufacturer’s recommendations (Clontech, Palo
Alto, CA) as previously described [14]. ImageQuant image analysis
software (Molecular Dynamics, Inc., Sunnyvale, CA) was used for
data acquisition of intensities using ‘‘volume’’ and ‘‘local background’’
options. Microsoft Excel was employed for data manipulation. Back-
ground was determined from the average signal of 6 previously de-
termined non-data-bearing areas on the array. This background value
was subtracted from all signal intensities and the resulting values were
then normalized by dividing by the average mean value of all signal
intensities on each ﬁlter (normalization by global means) [15]. Signals
for individual genes on CC arrays were compared to those on MC
arrays to estimate ‘‘relative transcriptional ratio’’. Those ratios rep-
resenting a 2-fold or greater signal change were considered to be ‘‘up-
regulated’’ or ‘‘down-regulated’’ genes.
2.7. Western blot analysis
Total cell extracts were prepared by homogenizing puriﬁed HUVEC
in cold RIPA buﬀer for 15 min (20 mM Tris–HCl, pH 7.5, 150 mM
NaCl, 1 mM ethylenediamine tetraacetic acid, 1 mM ethylene glycol
tetraacetic acid, 1% Triton X-100; 1 mM 2-mercaptoethanol, 1 mM
Na3VO4; 1 lg/ml leupeptin, and 1 mM phenylmethylsulfonyl ﬂuoride).
Samples were centrifuged at 14 000 rpm for 15 min at 4 C. The su-
pernatant was collected and protein concentration determined using
BioRad Standard Protein Assay Reagent (Hercules, CA). Lysates (25
lg per well) were subjected to SDS–PAGE and transferred to Immo-
bilon-P membranes (Millipore Corp. Burlington, MA). The mem-
branes were immunoblotted with the following primary antibodies:
anti-integrin av monoclonal antibody (SC-9969); anti-integrin b1
polyclonal antibody (SC-6622); anti-MAPK(p42) monoclonal anti-
body (SC-1647); anti-Rad51 polyclonal antibody (SC-6862); and anti-DNA-PKCS polyclonal antibody (SC-1552) (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). Horseradish peroxidase-conjugated goat anti-
rabbit or donkey anti-goat secondary antibodies and the SuperSignal
West Pico Chemiluminescent Substrate (Pierce, Rockford, IL) system
were used to visualize bands. Detection of b-actin as an internal con-
trol was performed on membranes using an anti-actin-HRP goat
polyclonal antibody (SC-1616, Santa Cruz Biotechnology). Nuclear
rather than total cell extracts were employed for Western blot analysis
of ataxia telangiectasia gene (ATM) expression. Bead-isolated HU-
VEC were placed in lysis buﬀer (10 mM Tris–HCl, pH 7.4, 10 mM
NaCl, 3 mMMgCl2, and 0.5% NP-40) and incubated for 5 min on ice.
The nuclear fraction was collected by centrifugation at 2000 g for 5
min at 4 C and then processed as above for total cell extracts. Im-
munoblot detection of ATM was performed using a goat polyclonal
anti-ATM antibody (SC-7128, Santa Cruz Biotechnology, Santa Cruz,
CA). Autoradiographs were scanned using a Canon CanoScan
FB1200S scanner and quantiﬁed using Scion Image software.
2.8. Neutralizing antibody against VEGF
HUVEC were plated in EGM-2 medium on Transwell inserts
(Corning Costar) for 16 h. HUVEC and trypsinized GFP-U87 cells
were washed two times with EBM-2 medium. GFP-U87 cells were
plated in the wells at a 1:10 HUVEC:GFP-U87 ratio to establish
‘‘physically separated’’ CCs. VEGF inhibition was performed by
adding 100 ng/ml anti-human VEGF-165 monoclonal antibody (R&D
Systems, Inc., Minneapolis, MN) to the wells. Mouse IgG (Sigma, St.
Louis, MO) was used as the negative control. Cells were trypsinized
and viability of HUVEC was determined by trypan blue exclusion.
2.9. Neutralizing antibody against aV b3 integrins (vitronectin receptor)
HUVEC were plated in EGM-2 medium on Transwell inserts as
described above. Mouse anti-human integrin aVb3 (vitronectin re-
ceptor) monoclonal antibody (MAB1976, Chemicon International,
Temecula, CA) at a concentration of 10 lg/ml was added to the wells.
Mouse IgG (Sigma, St. Louis, MO) was used as the negative control.
Cells were trypsinized and viability of HUVEC was determined by
trypan blue exclusion.3. Results
3.1. CC with GFP-U87 cells protects HUVEC from
radiation-induced apoptosis
IR-induced apoptosis of HUVEC grown in ‘‘physically
separated’’ CC with GFP-U87 cells was compared with IR-
induced apoptosis of HUVEC grown in MC. We measured
HUVEC apoptosis at time 0 just prior to loading GFP-U87
cells in the bottom wells of TransWell chambers. Baseline
HUVEC apoptosis in EGM-2 growth medium was
2.0 1.32% and is represented as the control (CTL) in Fig. 1.
By 24 h of CC, there was no diﬀerence in apoptosis between
non-irradiated MC (8.41 0.99%) and non-irradiated CC
(7.60 2.52%). However, following exposure to 300 cGy, a
signiﬁcant increase in apoptosis was detected in HUVEC
grown in MC (MC+ IR, 36.27 12.36%) compared with
HUVEC grown in CC with GFP-U87 cells (CC+ IR,
8.72 2.38%, P ¼ 0:0012, t test). These data demonstrate that
CC with GFP-U87 cells protects HUVEC from radiation-
induced apoptosis and illustrate that the tumor cells and en-
dothelial cells do not have to be in physical contact to establish
the protective eﬀect.
3.2. Diﬀerences in transcriptional proﬁles of HUVEC
grown in MC versus CC
DNA array analysis was employed to investigate if HUVEC
resistance to IR-mediated apoptosis was associated with dif-
ferential gene expression and/or RNA accumulation. Total
RNA was isolated from HUVEC and ratios of the hybrid-
Fig. 2. Representative western blot of selected up-regulated HUVEC
gene products and the eﬀects of treatment with anti-VEGF antibody.
Relative ratios of gene products of integrin av, integrin b1,
MAPK(p42), Rad51, DNA-PKCS, and ATM from cell extracts of
HUVEC grown in MC and CC are shown. The elevation in protein
levels coincides with the increases in gene expression detected by DNA
array analyses. Treatment with anti-VEGF antibody in CC (CC+Ab)
decreases the expression of integrin av, integrin b1, DNA-PKCS, and
ATM, but not Rad51 or MAPK(p42).
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Fig. 1. CC with GFP-U87 cells protects HUVEC from radiation-
induced apoptosis. The eﬀects of IR on apoptosis were evaluated in
HUVEC grown in MC compared with HUVEC grown in CC with
GFP-U87 cells. Attached and ﬂoating HUVEC were centrifuged, and
membranes were stained with DAPI. Apoptotic bodies from 10 ﬁelds
from duplicated membranes were counted. Following 300 cGy, a sig-
niﬁcant increase (P¼ 0.0012) in HUVEC apoptosis was detected in
MC (36.27 12.36%) compared with CC (8.72 2.38%).
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calculated. CC of HUVEC with GFP-U87 cells was associated
with an increase in HUVEC mRNA of 82 genes. These genes
were then placed into functional groups. Genes encoding
proteins that regulate cell cycle, growth factor related proteins
and cell adhesion molecules represented the most common
functional groups that were up-regulated by CC. Eight selected
genes with RNA expression ratios greater than 10-fold are
presented in Table 1. These genes encode integrins av, a6, and
b1, cell cycle regulatory/DNA repair proteins cyclin A, ATM,
the catalytic subunit of DNA-dependent protein kinase (DNA-
PKCS), Rad51, and MAPK(p42). These ﬁndings demonstrate
that tumor cells modify the transcriptional patterns of endo-
thelial cells, including genes which participate in the response
to the genotoxic stress.
3.3. Increases in HUVEC gene expression induced by
GFP-U87 cells result in an increase in protein production
Western blot analysis was performed on HUVEC extracts to
determine if the relative RNA expression ratios detected by
cDNA array analysis reﬂect changes in protein expression. The
relative protein levels of the 8 genes with RNA expression
ratios greater than 10-fold were determined. The protein levels
of all 8 genes including integrin av, integrin b1, MAPK(p42),
Rad51, DNA-PKCS, MAPK(p42) and ATM were elevated in
HUVEC grown in CC with GFP-U87 cells compared with
HUVEC grown in MC (MC, Fig. 2). Speciﬁcally, a 2-fold
increase in av and b1 integrin was detected following CC (1.97-
fold and 2.11-fold, respectively). Protein levels of MAPK(p42)
and Rad51 were also increased (1.40-fold and 1.67-fold, re-Table 1
HUVEC genes exhibiting a 10-fold increase in transcription following
CC with GFP-U87 cells
Gene Ratio
Integrin av; vitronectin receptor a subunit 22.1
Cyclin A 17.6
ATM gene 17.3
DNA-PKCS 15.1
Integrin a6 subunit 11.8
Integrin b1; ﬁbronectin receptor b subunit 11.2
DNA repair protein RAD51 10.9
MAPK(p42) 10.2spectively) with ATM (2.51-fold) and DNA-PKCS (3.38-fold)
exhibiting the greatest increase.
3.4. Growth stimulation and up-regulation of gene expression
in HUVEC is due in part to VEGF production by
GFP-U87 cells
We have previously reported that conditioned medium from
U87 glioblastoma cells contains 12.7 ng of VEGF. [5] In our
current CC model, we detected 20 ng/ml VEGF in GFP-U87
conditioned medium to which HUVEC are exposed. To eval-
uate the eﬀects of VEGF neutralization, we treated HUVEC
MCs and CCs with anti-VEGF neutralizing antibody (Ab).
We previously reported that treatment with anti-VEGF anti-
body potentiates IR-mediated HUVEC cytotoxicity. [5] A
signiﬁcant reduction in HUVEC cell number was observed in
CC (CC¼ 24.45 4.4 103, CC+Ab¼ 5.63 0.53 103, P <
0:001) but not in MC (MC¼ 12.75 0.79 103, MC+Ab¼
15.53 0.48 103, Fig. 3A) following treatment with anti-
VEGF antibody. These ﬁndings indicate that VEGF released
by GFP-U87 cells promotes the growth of HUVEC in CC.
We also evaluated the eﬀects of VEGF neutralization on
HUVEC protein expression. Using Western blot analysis, we
determined that treatment with anti-VEGF antibody de-
creased the expression of integrin av (CC¼ 1.97, CC+Ab¼
1.05), integrin b1 (CC¼ 2.11, CC+Ab¼ 1.46), DNA-PKCS
(CC¼ 3.38, CC+Ab¼ 1.59), and ATM (CC¼ 2.51, CC+
Ab¼ 1.24), but not Rad51 (CC¼ 1.67, CC+Ab¼ 1.64) or
MAPK(p42) (CC¼ 1.4, CC+Ab¼ 1.32, Fig. 2). Taken to-
gether, these ﬁndings suggest that HUVEC growth stimulation
and up-regulation of HUVEC proteins, including integrin av,
integrin b1, DNA-PKCS, and ATM, are mediated, in part, by
GFP-U87-derived VEGF.
3.5. Genes other than VEGF participate in the survival of
HUVEC grown in CC
To validate the functional signiﬁcance of our data, we em-
ployed neutralizing antibodies to the vitronectin receptor (the
aVb3 integrin complex). We selected anti-integrin antibody
because theHUVECgene proﬁling data (Table 1) demonstrated
that the vitronectin receptor a subunit exhibited the greatest up-
regulation (22.1 expression ratio) following CC with GFP-U87
cells. HUVEC MCs and HUVEC+GFP-U87 CCs were
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Fig. 3. Eﬀect of neutralizing antibodies on HUVEC growth. HUVEC
were grown in MC or in CC with GFP-U87 cells. Cultures were treated
with anti-human VEGF-165 (A) or anti-human integrin aVb3 (vitro-
nectin receptor) (B) monoclonal antibody. Viability was determined by
trypan blue exclusion. Neither anti-VEGF nor anti-integrin inhibited
the growth of HUVEC MCs (MC versus MC+Ab). A signiﬁcant
decrease (P < 0:001) in HUVEC cell number was observed in CCs
treated with neutralizing antibodies to VEGF and aVb3 integrin (CC
versus CC+Ab).
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evaluated 48 h later. A signiﬁcant reduction in HUVEC cell
number was observed in CC (CC¼ 12.0 0.3 103,
CC+Ab¼ 0.40 0.10 103, P < 0:001) but not in MC
(MC¼ 2.6 0.30 103, MC+Ab¼ 2.8 0.5 103, Fig. 3B)
following treatment with anti-integrin antibody. These data
demonstrate that up-regulation of aV integrin gene expression
by HUVEC following CC with GFP-U87 cells stimulates the
growth and survival of HUVEC.4. Discussion
In the present studies we report that CC of HUVEC with
GFP-U87 tumor cells protects HUVEC from IR-mediated ap-
optosis. These ﬁndings support our previous observations that
tumor cells inﬂuence the phenotype of endothelial cells [13].
Employing cDNA macroarray analysis, we investigated the
transcriptional proﬁles of HUVEC grown in CC and found a
>10-fold increase in the accumulation of RNAs for genes en-
coding cell adhesionmolecules andproteins that regulate the cell
cycle and DNA repair. Importantly, we detected an increase in
the expression of ATM,Rad51, DNA-PKCS and cyclin Awhich
may be associated with the decrease in radiation-induced ap-
optosis of HUVEC grown in CC. One limitation of our current
studies is that kinases, such as ATM and DNA-PKCS, are reg-
ulated by post-translational modiﬁcations. Our ﬁndings do not
conﬁrm the production of functional proteins but do suggest
that tumor cells can alter endothelial cell gene transcription
thereby promoting survival and radioresistance.The current studies raise questions regarding how genes with
diﬀerential basal expression respond to IR treatment. To ad-
dress these questions we performed expressional proﬁling of
HUVEC MCs and CCs using GeneFilter arrays (Research
Genetics, Invitrogen, Life Technologies, Carlsbad, CA). We
found that the expression of 4 genes in Table 1 (ATM,
MAPK(p42), Rad51 and integrin b1) was up-regulated in CC
during the ﬁrst 24 h following exposure to 3 Gy (data not
shown). Complete analysis of these data is underway. In sep-
arate studies mock-transfected U87 cells (U87-Lux8) treated
with 3 Gy demonstrated up-regulation of several genes asso-
ciated with positive regulation of angiogenesis, including TGF-
a, neuregulin (heregulin-b3) and VEGF. These ﬁndings may
also explain the increase in endothelial survival observed in
irradiated CCs comparing with irradiated MCs [16].
Tumor cells develop resistance to anti-cancer therapy as a
result of the mutations that generate resistant phenotypes from
an inherently unstable genome. The notion that the vascular
components of tumors are attractive targets for anti-cancer
therapy stems from the belief that endothelial cells are derived
from ‘normal’ host cells and, therefore, are less likely to de-
velop resistance to anti-cancer regimens. However, our data
challenge this conventional view in that while tumor cells de-
velop resistance to therapy, the interaction between tumor cells
and endothelial cells may also render ‘normal cells’ resistant to
anti-neoplastic agents. We further demonstrate using cDNA
array analysis that interactions between tumor cells and en-
dothelial cells lead to the activation of endothelial cell genes
whose products mediate cell growth and decreased suscepti-
bility to IR-induced apoptosis. Additionally, our ﬁndings in-
dicate that VEGF secretion by tumor cells augments the
expression of these endothelial cell genes. We hypothesize that
the paracrine up-regulation of genes, which mediate survival
following IR exposure, may alter the radioresistance of tumor-
associated endothelial cells and, therefore, may contribute to
the overall resistance of tumors to conventional treatments.References
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